Vascular targeting of solid tumoursa major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas

European Journal of Cancer

Volumn 36, Issue 14, 2000, Pages 1833-1843

  Landuyt, W ^a   Verdoes, O ^a   Darius, D O ^a   Drijkoningen, M ^a   Nuyts, S ^a   Theys, J ^b   Stockx, L ^a   Wynendaele, W ^a   Fowler, J F ^a,c   Maleux, G ^a   Van Den Bogaert, W ^a   Anne J ^b   Van Oosterom, A ^a   Lambin, P ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Angiography; Antitumour therapy; Combretastatin A 4 prodrug; Growth delay; Tumour necrosis; Tumour volume; Vascular targeting

Indexed keywords

COMBRETASTATIN;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DOSE RESPONSE; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; SOLID TUMOR; TARGET ORGAN; TUMOR NECROSIS; TUMOR VOLUME; VASCULARIZATION;

ANGIOGRAPHY, DIGITAL SUBTRACTION; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; NEOVASCULARIZATION, PATHOLOGIC; RATS; RHABDOMYOSARCOMA; STILBENES; TUMOR CELLS, CULTURED;

EID: 17544397865     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00173-8     Document Type: Article

References (38)

1. Denekamp J. Review article. angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy Br. J. Radiol. 66:1993;181-196.
2. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol. Oncol. 23:1984;217-225.
3. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3:1992;65-71.
4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
5. Folkman J. Tumor angiogenesis. therapeutic implications N. Engl. J. Med. 285:1971;1182-1186.
6. Hanahan D. A flanking attack on cancer. Nature Med. 4:1998;13-14.
7. Sipos E.P., Tamargo R.J., Weingart J.D., Brem H. Inhibition of tumor angiogenesis. Ann. N.Y. Acad. Sci. 732:1994;263-272.
8. Auerbach W., Auerbach R. Angiogenesis inhibition. a review Pharmacol. Ther. 63:1994;265-311.
9. Molema G., Griffioen A.W. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Trends Immunol. Today. 19:1998;392-394.
10. Barinaga M. Designing therapies that target tumor blood vessels. Science. 275:1997;482-484.
11. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2:1996;689-692.
12. Chaplin D.J., Pettit G.R., Parkins C.S., Hill S.A. Antivascular approaches to solid tumours therapy. evaluation of tubulin binding agents Br. J. Cancer. 74:1996;S86.
13. Baguley B.C., Calveley S.B., Crowe K.K., Fray L.M., O'Rourke S.A., Smith G.P. Comparison of the effects of flavone acetic acid, fostriecin and homoharringtonine and tumour necrosis factor-α on colon 38 tumours in mice. Eur. J. Cancer Clin. Oncol. 25:1989;263-269.
14. Song C.W. Effect of local hyperthermia on blood flow and microenvironment. a review Cancer Res. 44:1984;4721s-4730s.
15. Reinhold H.S., Zurcher C., Van den Berg-Blok A.E. Differential heat sensitivity of tumour microvasculature. Eur. J. Cancer. 26A:1990;541-543.
16. Hill S., Williams K.B., Denekamp J. Vascular collapse after flavone acetic acid. a possible mechanism of its anti-tumour action Int. J. Cancer Clin. Oncol. 25:1989;1419-1424.
17. Watanabe N., Niitsu Y., Umeno H.et al. Toxic effect of tumour necrosis factor on tumour vasculature in mice. Cancer Res. 48:1988;2179-2183.
18. Burrows F.J., Thorpe P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA. 90:1993;8996-9000.
19. Seon B.K., Matsuno F., Haruta Y., Kondo M., Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Cancer Res. 3:1997;1031-1044.
20. Baguley B.C., Holdaway K.M., Thomsen L.L., Zhuang L., Zwi L.J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine. evidence for a vascular mechanism Eur. J. Cancer. 27A:1991;482-487.
21. Hill S.A., Sampson L.E., Chaplin D.J. Anti-vascular approaches to solid tumor therapy. evaluation of vinblastine and flavone acetic acid Int. J. Cancer. 63:1995;119-123.
22. Pettit G.R., Singh S.B., Boyd M.R.et al. Antineoplastic agents 291. Isolation and synthesis of combretastatins A-4, A-5 and A-6. J. Med. Chem. 291:1995;1666-1672.
23. Lin C.M., Singh S.B., Chu P.S.et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin. a structure-activity study Mol. Pharmacol. 34:1988;200-208.
24. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1997;1829-1834.
25. Lingyun L., Rojiani A., Siemann D.W. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate. effects on radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 42:1998;899-903.
26. Horsman M.R., Ehrnrooth E., Ladekarl M., Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;895-898.
27. Hermens A.F., Barendsen G.W. Cellular proliferation patterns in an experimental rhabdomyosarcoma in the rat. Eur. J. Cancer. 3A:1967;361-369.
28. Dorr R.T., Dvorakova K., Snead K., Alberts D.S., Salmon S.E., Pettit G.R. Antitumor activity of combretastatin A-4 phosphate, a natural product tubulin inhibitor. Invest. New Drugs. 14:1996;131-137.
29. Iyer S., Chaplin D.J., Rosenthal D.S., Boulares A.H., Li L.Y., Smulson M.E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific anti-angiogenesis agent combretastatin A-4. Cancer Res. 58:1998;4510-4514.
30. Chaplin D.J., Pettit G.R., Hill S.A. Anti-vascular approaches to solid tumour therapy. evaluation of combretastatin A-4 phosphate Anticancer Res. 19:1999;189-196.
31. Denekamp J., Dasu A., Waites A. Vasculature and microenvironmental gradients. the missing links in novel approaches to cancer therapy? Adv. Enzyme Regul. 38:1998;281-299.
32. Mahadevany M.S., Meager A., Fiers W., Lewis G.P., Hart I.R. Role of tumor necrosis factor in flavone acetic acid induced vascular shutdown. Cancer Res. 50:1990;5537-5542.
33. Denekamp J., Hill S.A., Hobson B. Vascular occlusion and tumour cell death. Eur. J. Cancer Clin. Oncol. 19:1983;271-275.
34. Landuyt W, Theys J, Nuyts S, et al. Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors with different sizes. Cancer Invest 2000, in press.
35. Lambin P., Theys J., Landuyt W.et al. Colonisation of Clostridium in the body is restricted to hypoxic and nectrotic areas of tumours. Anaerobe. 4:1998;183-188.
36. El-Zayat A.A.E., Degen D., Drabek S., Clark G.M., Pettit G.R., Von Hoff D.D. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anti-Cancer Drugs. 4:1993;19-25.
37. Lambin Ph., Kramar A., Haie-Meder C.et al. Tumour size in cancer of the cervix. Acta Oncol. 37:1998;729-734.
38. Dubben H.-H., Thames H.D., Beck-Bornholdt H.-P. Tumor volume. a basic and specific response predictor in radiotherapy Radiother. Oncol. 47:1998;167-174.